Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (colonocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: arcitumomab, labetuzumab, labetuzumab govitecan +2 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4796
Sealed predictions
- CEACAM5 in dopamine neurons, braak+0.02 (p 0.965) → -0.24 (p 0.534)receipt 4804
Swarm cases
receipt 4804: CEACAM5 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.460, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.302, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.43 (p 0.077, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.09, sign flips 0; without severely affected donors -0.19 (p 0.460, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CEACAM5 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts